See how molecular profiling works and how it's helping in the fight against NSCLC.
Help us spread the word. Our goal is to change the fight against lung cancer, and you can make a difference by sharing.
For decades, doctors treated lung cancer primarily based on its appearance under the microscope. For patients, that usually meant a “one-size-fits-all” approach when it came to formulating their treatment plan.1,2
Now, doctors understand that there are different types of lung cancer, which can be driven by different genetic factors. Molecular profiling — testing your tumor for molecular biomarkers — can help doctors tailor treatment plans for certain patients based on the genetic makeup of their tumors. It may also help determine some tumors’ potential for spreading or recurring.3-6
The Role of Biomarkers
Molecular biomarkers are the distinctive fingerprints of gene mutations inside tumor cells that may cause them to be cancerous. A gene mutation is a change in the DNA sequence of a gene.3,7,8
The presence of biomarkers in your molecular profile could reveal what is driving your cancer. And it may provide clues and information to your healthcare team that could help them develop a treatment plan using approved biomarker-driven medicines, or possibly enroll you in a clinical trial.5,6,9,10
The Future Is Here
Some people with NSCLC will test positive for a mutation that may be treatable with a biomarker- driven therapy. Others may test positive for a biomarker that may make them eligible for a clinical trial. Still others may not test positive for any biomarkers at all.5,6,9,10
The fact is, genetics research is continuing, and more lung cancer-related biomarkers are being discovered. This is significant because with each newly discovered biomarker comes the possibility of finding biomarker-driven medicines treatments for specific subtypes of tumors.5,6
Talk to your doctor and ask if molecular profiling is right for you. This Interactive Discussion Guide can help you start the conversation.